| 7:40 AM | Welcome and Introduction | Peter B. Berger, MD (Speaker)
|
| 8:00 AM | Antiplatelet Controversy: Critical Review of the Clinical Trials | Peter B. Berger, MD (Moderator) Robert A. Harrington, MD (Moderator)
|
| 8:00 AM | What’s New in the Guidelines for ACS & AMI | Robert A. Harrington, MD (Speaker)
|
| 8:10 AM | Prasugrel: New Data from TRITON-TIMI 38 | Stephen D. Wiviott, MD (Speaker)
|
| 8:20 AM | What are the Key Challenges for Using Prasugrel in the Lab? | Victor Serebruany, Other (Speaker)
|
| 8:30 AM | Should we Change the Clopidogrel Dose Following Current OASIS 7? | Robert A. Harrington, MD (Speaker)
|
| 8:40 AM | Lessons Learned from the PLATO Trial | Peter B. Berger, MD (Speaker)
|
| 8:50 AM | Why I am not Excited About Ticagrelor | Neal S. Kleiman, MD (Speaker)
|
| 9:00 AM | Panel Discussion: How we use Antiplatelet Therapy for Patients with ACS & AMI in 2010 | Peter B. Berger, MD (Moderator) Robert A. Harrington, MD (Panelist) Neal S. Kleiman, MD (Panelist) Sunil V. Rao, MD (Panelist) Victor Serebruany, Other (Panelist) Stephen D. Wiviott, MD (Panelist)
|
| 9:15 AM | New Antiplatelet Agents | Peter B. Berger, MD (Moderator) Robert A. Harrington, MD (Moderator)
|
| 9:15 AM | What do the CHAMPION Trial Results Tell us About Cangrelor and Antiplatelets in General? | Steven R. Steinhubl, MD (Speaker)
|
| 9:25 AM | PAR-1 Inhibitors: Update on SCH 530348 and E5555 | David J. Moliterno, MD (Speaker)
|
| 9:35 AM | Old Antiplatelet Agents - New Strategies | Peter B. Berger, MD (Moderator) Robert A. Harrington, MD (Moderator)
|
| 9:35 AM | ACS and NSTEMI: GP IIb/IIIa Inhibitors and PCI: For Whom and for How Long? How Early Should We Give Them? | George W. Vetrovec, MD (Speaker)
|
| 9:45 AM | Antiplatelet Therapy for Non-PCI Patients: The Impact on Primary and Secondary Prevention | Peter B. Berger, MD (Speaker)
|
| 9:55 AM | Antiplatelet Therapy for Elective PCI: What Should be the Antiplatelet of Choice | Sunil V. Rao, MD (Speaker)
|
| 10:05 AM | Antiplatelet Responsiveness and Resistance | Paul A. Gurbel, MD (Moderator) David J. Moliterno, MD (Moderator)
|
| 10:05 AM | What Lessons Should be Learned from the POPular Study? | Neal S. Kleiman, MD (Speaker)
|
| 10:15 AM | Insights into Factors Affecting Responsiveness to Aspirin and Clopidogrel: Interactions with Other Medications and Platelet Turnover Rate | Paul A. Gurbel, MD (Speaker)
|
| 10:25 AM | Prasugrel - New Pharmacodynamic Data: SWAP and OPTIMUS-3 Trials, and Ticagrelor on Platelet Function | Dominick J. Angiolillo, Other (Speaker)
|
| 10:35 AM | Does PPI Impact on Platelet Responsiveness? | Subhash Banerjee, MD (Speaker)
|
| 10:45 AM | Platelet Function Testing: Which one Should we Perform and how to Interpret the Data? | Dominick J. Angiolillo, Other (Speaker)
|
| 10:55 AM | GRAVITAS Update | Matthew J. Price, MD (Speaker)
|
| 11:05 AM | Genotyping: Which one Should we Perform, how to Interpret the Data and is it Ready for Clinical Practice? | Paul A. Gurbel, MD (Speaker)
|
| 11:15 AM | DEBATE: Should We Tailor Antiplatelet Therapy Based on Platelet Function Testing and Genotyping? | Peter B. Berger, MD (Speaker) Matthew J. Price, MD (Speaker)
|
| 11:15 AM | Pro | Matthew J. Price, MD (Speaker)
|
| 11:22 AM | Con | Peter B. Berger, MD (Speaker)
|
| 11:29 AM | Discussion |
|
| 11:35 AM | Bleeding: Definition and Prevention | Sunil V. Rao, MD (Moderator) Ron Waksman, MD (Moderator)
|
| 11:35 AM | Pitfalls of the Current Bleeding Definition | Sunil V. Rao, MD (Speaker)
|
| 11:45 AM | Is it Possible to Develop a Universal Bleeding Definition? | Victor Serebruany, Other (Speaker)
|
| 11:55 AM | Nuisance Bleeding: What have we Learned so far | Ron Waksman, MD (Speaker)
|
| 12:05 PM | Bleeding is not Necessarily Harmful | Sunil V. Rao, MD (Speaker)
|
| 12:15 PM | Panel Discussion: Who Should be the one to Develop a new Universal Definition for Bleeding? | Roxana Mehran, MD (Panelist) Sunil V. Rao, MD (Moderator) Victor Serebruany, Other (Panelist) Ron Waksman, MD (Panelist) Stephen D. Wiviott, MD (Panelist)
|
| 12:35 PM | Lunch & Visit the Exhibits |
|
| 1:20 PM | Antithrombin Controversy for ACS and Primary PCI | Peter B. Berger, MD (Moderator) Neal S. Kleiman, MD (Moderator)
|
| 1:20 PM | DEBATE : What Should be the Optimal Upstream Therapy for Patients with ACS? | Neal S. Kleiman, MD (Speaker) Roxana Mehran, MD (Speaker)
|
| 1:20 PM | Bivalirudin: One Drug Fits it all | Roxana Mehran, MD (Speaker)
|
| 1:30 PM | Low Molecular Weight Heparins with or without IIb/IIIa Antagonists | Neal S. Kleiman, MD (Speaker)
|
| 1:40 PM | Optimal Antithrombin Therapy in Elective PCI | Robert A. Harrington, MD (Speaker)
|
| 1:50 PM | Antiplatelet Effects of Anticoagulants: Potential of Oral Factor Xa Inhibitors to Prevent Arterial Thrombosis | David J. Moliterno, MD (Speaker)
|
| 2:00 PM | The REG 1 Anticoagulation System for Patients with ACS: The Advantages of Anti IX Inhibitor | Thomas J. Povsic, MD, PhD (Speaker)
|
| 2:10 PM | Panel Discussion: What Should be the Upstream Therapy in ACS: Bivalirudin, Low Molecular Heparin, Fondaparinux or IIb/IIIa Inhibitors? | Peter B. Berger, MD (Moderator) Neal S. Kleiman, MD (Panelist) Roxana Mehran, MD (Panelist) Thomas J. Povsic, MD, PhD (Panelist) Ron Waksman, MD (Panelist)
|
| 2:20 PM | Lessons Learned from the HORIZONS AMI Study: New Data on Bleeding and Predictors for Stent Thrombosis | Roxana Mehran, MD (Speaker)
|
| 2:30 PM | Utilization of Rescue and Facilitated Angioplasty for Primary PCI: Who Should Receive Lytic Therapy in 2010? | Bruno Scheller, Other (Speaker)
|
| 2:40 PM | Refreshment Break |
|
| 2:55 PM | STEMI Door-to-Balloon Time | Robert A. Harrington, MD (Moderator) Alice K. Jacobs, MD (Moderator)
|
| 2:55 PM | Time to Treatment (and Transport) Issues: Selection of Reperfusion Modality, and Primary Angioplasty with no On-Site Surgery | Robert A. Harrington, MD (Speaker)
|
| 3:05 PM | The Implications of the TRANSFER AMI Trial for Clinical Practice | Timothy D. Henry, MD (Speaker)
|
| 3:15 PM | Approaches to Shortening Door-to-Balloon Time: The Poland Experience | Dariusz Dudek, MD, PhD (Speaker)
|
| 3:25 PM | Integrating the EMS with Hospital Primary PCI Programs: The Washington DC Experience | Jim J. Augustine, MD (Speaker)
|
| 3:35 PM | Tele-medicine to Expedite Patients’ Transfer: The Cell Phone Experience | Lowell F. Satler, MD (Speaker)
|
| 3:45 PM | Medical Societies’ Initiatives to Reduce Door-to-Balloon Time: A Progress Report | Alice K. Jacobs, MD (Speaker)
|
| 3:55 PM | DEBATE | Jeff A. Brinker, MD (Speaker) Mark A. Turco, MD (Speaker)
|
| 3:55 PM | Surgical Back-up is not Required for Primary PCI | Mark A. Turco, MD (Speaker)
|
| 4:05 PM | On-Site Surgical Back-up is Critically Important | Jeff A. Brinker, MD (Speaker)
|
| 4:15 PM | Panel Discussion: How Should we Optimize Door-to-Balloon Time for STEMI in 2010? | Jim J. Augustine, MD (Panelist) Dariusz Dudek, MD, PhD (Panelist) Timothy D. Henry, MD (Panelist) Alice K. Jacobs, MD (Moderator) Lowell F. Satler, MD (Panelist) Mark A. Turco, MD (Panelist)
|
| 4:25 PM | Myocardial Preservation and Restoration | Howard A. Cohen, MD (Moderator) Dariusz Dudek, MD, PhD (Moderator)
|
| 4:25 PM | Cell Therapy for Myocardial Regeneration | Timothy D. Henry, MD (Speaker)
|
| 4:35 PM | Infused AMI: Intercoronary IIb/IIIa Infusion for STEMI | Brijeshwar S. Maini, MD (Speaker)
|
| 4:45 PM | New Strategies and Devices to Manage Cardiogenic Shock | Howard A. Cohen, MD (Speaker)
|
| 4:55 PM | Drug Eluting Stents in AMI: A Proven Strategy? | James Hermiller, MD (Speaker)
|
| 5:05 PM | How to Handle Acute Shock and Acute Chronic Heart Failure | Steven W. Boyce, MD (Speaker)
|
| 5:15 PM | Thrombectomy or Aspiration Devices for Thrombus Management: How Strong is the Evidence? | Dariusz Dudek, MD, PhD (Speaker)
|
| 5:25 PM | MILD Hypothermia Combined with PCI for ALL Resuscitated Victims of Cardiac Arrest | Michael R. Mooney, MD (Speaker)
|
| 5:35 PM | Adjourn |
|